---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-106282"
form_type: "8-K"
ticker: "RIGL"
cik: "0001034842"
company_name: "RIGEL PHARMACEUTICALS INC"
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:31:11.217335+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rigel Q3 net income $27.9M, raises 2025 revenue guidance to $285-290M

## Summary
- Q3 net income $27.9M ($1.46 diluted EPS) vs $12.4M ($0.70) in Q3 2024.
- Total revenue $69.5M, record net product sales $64.1M (+65% YoY).
- Raises 2025 total revenue guidance to ~$285-290M (prior $270-280M); product sales $225-230M.
- TAVALISSE sales $44.7M (+70%), GAVRETO $11.1M (+56%), REZLIDHIA $8.3M (+50%).
- R289 Ph1b dose expansion underway; Lilly terminates CNS collaboration (60-day effect).

## SEC filing metadata
- accession: 0001104659-25-106282
- form_type: 8-K
- ticker: RIGL
- cik: 0001034842
- company_name: RIGEL PHARMACEUTICALS INC
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1034842/000110465925106282/0001104659-25-106282-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1034842/000110465925106282/tm2530133d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-106282
- JSON: https://secwatch.observer/filing/0001104659-25-106282.json
- Plain text: https://secwatch.observer/filing/0001104659-25-106282.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.